NYSE:GEN Genesis Healthcare (GEN) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free GEN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$24.43▼$24.9150-Day Range$0.18▼$0.6052-Week Range$0.40▼$1.37Volume19.91 million shsAverage Volume4.10 million shsMarket Capitalization$15.87 billionP/E Ratio27.59Dividend Yield2.01%Price Target$26.40 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipTrendsStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipTrends Get Genesis Healthcare alerts: Email Address Genesis Healthcare MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside6.3% Upside$26.40 Price TargetShort InterestN/ADividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingSelling Shares$18.33 M Sold Last QuarterProj. Earnings Growth5.52%From $1.63 to $1.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsBusiness Services Sector276th out of 310 stocksPrepackaged Software Industry184th out of 201 stocks 1.3 Analyst's Opinion Consensus RatingGenesis Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGenesis Healthcare has only been the subject of 2 research reports in the past 90 days.Read more about Genesis Healthcare's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GEN. Previous Next 2.5 Dividend Strength Dividend YieldGenesis Healthcare pays a meaningful dividend of 3.05%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenesis Healthcare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genesis Healthcare is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Genesis Healthcare will have a dividend payout ratio of 29.07% next year. This indicates that Genesis Healthcare will be able to sustain or increase its dividend.Read more about Genesis Healthcare's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GEN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Genesis Healthcare this week, compared to 5 articles on an average week.Search Interest11 people have searched for GEN on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Genesis Healthcare to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genesis Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,330,000.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Genesis Healthcare is held by insiders.Percentage Held by Institutions82.08% of the stock of Genesis Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genesis Healthcare's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Genesis Healthcare are expected to grow by 5.52% in the coming year, from $1.63 to $1.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genesis Healthcare is 27.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Genesis Healthcare is 27.59, which means that it is trading at a more expensive P/E ratio than the Business Services sector average P/E ratio of about 26.64. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Genesis Healthcare Stock (NYSE:GEN)Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.Read More Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. GEN Stock News HeadlinesMay 15, 2024 | marketbeat.com3 Hot Buyback Plans Supporting Price Action in 2024Share repurchases are a controversial topic because they often do little more than hide the impact of share-based compensation or amplify (at face value) sluggish earnings growth. However, as with the stocks today, share repurchases can drive shareholder value by reducing the share count.June 3 at 6:00 AM | investorplace.com3 Underappreciated Cybersecurity Stocks to Buy NowMay 28, 2024 | prnewswire.comGen Releases its Fiscal 2024 Social Impact ReportMay 27, 2024 | msn.comJoint Genesis Reviews (BioDynamix) Is The Joint Support Formula Effective? Real Benefits, Results, Side-Effects & User Views!May 26, 2024 | msn.comGenesis Dealer’s Catastrophic Oil Change, Botched Fix Pushes Infuriated Owner To LexusMay 22, 2024 | msn.comNew York Attorney General Secures $2 Billion Settlement with Genesis to Compensate InvestorsMay 21, 2024 | finance.yahoo.comGenesis + HOCL to Showcase Revolutionary Clean Air Technology on 'Great Day Washington,' WUSA, Channel 9May 20, 2024 | forbes.comStarkey Executives Talk Hearing Aid Innovation, Developing Genesis AI, More In InterviewMay 17, 2024 | finance.yahoo.comGen Pledges To Help Close the Gender Gap in Europe’s Cybersecurity IndustryMay 16, 2024 | finance.yahoo.comInsider Sale: CFO Natalie Derse Sells 169,535 Shares of Gen Digital Inc (GEN)May 14, 2024 | msn.comGenesis thanks program for boosting reading levelsMay 14, 2024 | prnewswire.comDeepfakes, AI-Manipulated Audio, and Hijacked Social Media Surge in 2024May 13, 2024 | finance.yahoo.comStream Companies selected as Genesis Certified Digital Advertising VendorMay 11, 2024 | finance.yahoo.comGen Digital Full Year 2024 Earnings: EPS Misses ExpectationsMay 11, 2024 | msn.comCoshocton Public Health starts Coffee with a Doc seriesMay 10, 2024 | fool.comWhy Gen Digital Stock Zoomed 15% Higher TodayMay 10, 2024 | msn.comGreater QC Hispanic Chamber presents Multicultural Speaker SeriesMay 9, 2024 | reuters.comGen Digital beats quarterly revenue estimatesMay 9, 2024 | prnewswire.comGen Delivers Fifth Consecutive Year of Organic Growth and Record Profitability in Fiscal 2024May 8, 2024 | bizjournals.comCounty slashes rare incentives for Rodney Steven-linked Goddard housing projectMay 8, 2024 | msn.comNew study offers insight into genesis of spina bifidaMay 8, 2024 | finance.yahoo.comGenesis Unveils Emerging Technology, HOCl Atomizing, for 'Air Quality Awareness Week'May 7, 2024 | msn.comMental Health Minister Matt Doocey sought advice on ‘social impact bonds’ to fund servicesMay 7, 2024 | finance.yahoo.comStork Club Reproductive Care Benefits Expands its Centers of Excellence Provider Network with GENESIS Fertility & Reproductive MedicineMay 7, 2024 | msn.comIndegene IPO subscribed 1.67 times on Day 1 of offerSee More Headlines Receive GEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genesis Healthcare and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/13 Dividend2/15/2024Dividend Payable3/13/2024Last Earnings5/09/2024Ex-Dividend for 6/12 Dividend5/17/2024Today6/02/2024Dividend Payable6/12/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorBusiness Services Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:GEN Previous SymbolNYSE:SKH CUSIPN/A CIK1351051 Webwww.genesishcc.com Phone610-444-6350Fax302-636-5454Employees2,700Year FoundedN/APrice Target and Rating Average Stock Price Target$26.40 High Stock Price Target$29.00 Low Stock Price Target$25.00 Potential Upside/Downside+6.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio27.59 Forward P/E Ratio15.23 P/E GrowthN/ANet Income$836 million Net Margins17.83% Pretax Margin23.69% Return on Equity155.48% Return on Assets9.12% Debt Debt-to-Equity Ratio7.50 Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$2.80 billion Price / Sales5.68 Cash Flow$2.95 per share Price / Cash Flow8.42 Book Value($0.16) per share Price / Book-155.19Miscellaneous Outstanding Shares639,130,000Free Float618,038,000Market Cap$15.87 billion OptionableOptionable Beta0.84 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Robert H. Fish (Age 70)CEO & Director Comp: $411.5kMr. Thomas DiVittorio (Age 53)Exec. VP & CFO Comp: $565kMr. Paul David Bach (Age 62)COO & Exec. VP Comp: $630kMr. Stephen Scott Young (Age 49)Chief Accounting Officer & Treasurer Mr. Richard L. Castor (Age 66)Chief Information Officer & Sr. VP Mr. James W. Tabak (Age 62)Sr. VP of Admin. & Gov. Affairs Ms. Lori MayerVP of Investor Relations, Brand Management & Marketing CommunicationsMr. Michael Scott Sherman (Age 52)Sr. VP, Gen. Counsel, Sec. & Assistant Treasurer Mr. Larry BaiderSr. VP of People Strategy & OperationsDr. JoAnne Susan Reifsnyder R.N. (Age 62)Ph.D., Ph.D., ACHPN, MSN, MBA, RN, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer More ExecutivesKey CompetitorsNetEaseNASDAQ:NTESPalantir TechnologiesNYSE:PLTRSnowflakeNYSE:SNOWAutodeskNASDAQ:ADSKAtlassianNASDAQ:TEAMView All CompetitorsInsiders & InstitutionsCambridge Trust Co.Sold 420 shares on 5/30/2024Ownership: 0.001%Boston PartnersSold 2,557,857 shares on 5/28/2024Ownership: 2.358%Cetera Advisors LLCBought 1,912 shares on 5/24/2024Ownership: 0.003%Walleye Trading LLCBought 8,200 shares on 5/17/2024Ownership: 0.000%New Covenant Trust Company N.A.Bought 2,115 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GEN Stock Analysis - Frequently Asked Questions Should I buy or sell Genesis Healthcare stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GEN shares. View GEN analyst ratings or view top-rated stocks. What is Genesis Healthcare's stock price target for 2024? 5 brokerages have issued 1-year price objectives for Genesis Healthcare's shares. Their GEN share price targets range from $25.00 to $29.00. On average, they anticipate the company's share price to reach $26.40 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price. View analysts price targets for GEN or view top-rated stocks among Wall Street analysts. How were Genesis Healthcare's earnings last quarter? Genesis Healthcare, Inc. (NYSE:GEN) posted its quarterly earnings data on Thursday, May, 9th. The company reported $0.48 EPS for the quarter, meeting the consensus estimate of $0.48. The business had revenue of $967 million for the quarter, compared to analysts' expectations of $965.03 million. Genesis Healthcare had a trailing twelve-month return on equity of 155.48% and a net margin of 17.83%. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.46 earnings per share. How often does Genesis Healthcare pay dividends? What is the dividend yield for Genesis Healthcare? Genesis Healthcare declared a quarterly dividend on Thursday, May 9th. Investors of record on Monday, May 20th will be paid a dividend of $0.125 per share on Wednesday, June 12th. This represents a $0.50 annualized dividend and a dividend yield of 2.01%. The ex-dividend date is Friday, May 17th. Read our dividend analysis for GEN. Is Genesis Healthcare a good dividend stock? Genesis Healthcare (NYSE:GEN) pays an annual dividend of $0.50 per share and currently has a dividend yield of 3.05%. The dividend payout ratio is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GEN will have a dividend payout ratio of 29.07% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for GEN. What ETFs hold Genesis Healthcare's stock? ETFs with the largest weight of Genesis Healthcare (NYSE:GEN) stock in their portfolio include Global X Cybersecurity ETF (BUG), Amplify Cybersecurity ETF (HACK), First Trust Nasdaq Cybersecurity ETF (CIBR), ASYMshares ASYMmetric S&P 500 ETF (ASPY), First Trust S&P 500 Diversified Dividend Aristocrats ETF (RNDV), Invesco S&P 500 Equal Weight Technology ETF (RYT), VictoryShares Nasdaq Next 50 ETF (QQQN) and Invesco S&P 500 Equal Weight Technology ETF (RSPT). How will Genesis Healthcare's stock buyback program work? Genesis Healthcare declared that its board has initiated a stock repurchase plan on Thursday, May 9th 2024, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 23.1% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued. What guidance has Genesis Healthcare issued on next quarter's earnings? Genesis Healthcare updated its first quarter 2025 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of 0.520-0.540 for the period, compared to the consensus earnings per share estimate of 0.530. The company issued revenue guidance of $960.0 million-$970.0 million, compared to the consensus revenue estimate of $965.6 million. What other stocks do shareholders of Genesis Healthcare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genesis Healthcare investors own include Flaherty & Crumrine Preferred Securities Income Fund (FFC), Vaxart (VXRT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AT&T (T), Amarin (AMRN), Government Properties Income Trust (GOV), Advanced Micro Devices (AMD), Bausch Health Companies (BHC) and Who are Genesis Healthcare's major shareholders? Genesis Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.52%), Boston Partners (2.36%), Price T Rowe Associates Inc. MD (1.22%), LSV Asset Management (0.78%), Mirae Asset Global Investments Co. Ltd. (0.32%) and Swiss National Bank (0.27%). Insiders that own company stock include Natalie Marie Derse, Ondrej Vlcek and Peter A Feld. View institutional ownership trends. This page (NYSE:GEN) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genesis Healthcare, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.